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Summary
An 84-year-old man presented 5 years after bioprosthetic mitral valve replacement with three months of worsening dyspnea on exertion. A new mitral stenosis murmur was noted on physical examination, and an electrocardiogram revealed newly recognized atrial fibrillation. Severe mitral stenosis (mean gradient = 13 mmHg) was confirmed by transthoracic echocardiography. Transesophageal echocardiography revealed markedly thickened mitral bioprosthetic leaflets with limited mobility, and a massive left atrial thrombus (>4 cm in diameter) (Fig. 1A , B, C, D and Videos 1, 2, 3 and 4). Intravenous heparin was initiated, and 5 days later, he was taken to the operating room for planned redo mitral valve replacement and left atrial thrombus extraction. Intraoperative transesophageal echocardiography revealed near-complete resolution of the bioprosthetic leaflet thickening, and a mean mitral gradient of only 3 mmHg ( Fig. 2A , B, C and Videos 5, 6 and 7). The patient underwent resection of the massive left atrial thrombus (Fig. 2D ) but did not require redo mitral valve replacement. He was initiated on heparin (and transitioned to warfarin) early in the post-operative period, with complete resolution of dyspnea on exertion at 3-month follow-up. Bioprosthetic valve thrombosis is increasingly recognized as a cause of early prosthetic valve dysfunction (1, 2) . This case illustrates that bioprosthetic valve thrombosis may occur years after valve replacement; therefore, any deterioration in a patient's clinical status (new-onset dyspnea, heart failure or atrial fibrillation) warrants a thorough evaluation of the bioprosthetic valve with transesophageal echocardiography. In this case, initiation of anticoagulation obviated the need for redo mitral valve replacement. 
Video 1
Mid-esophageal 2-chamber TEE image reveals a massive left atrial mural thrombus and markedly thickened bioprosthetic mitral leaflets. View Video 1 at http:// movie-usa.glencoesoftware.com/video/10.1530/ERP-17-0004/video-1.
Video 6
Intraoperative mid-esophageal TEE image after extraction of the left atrial thrombus (compare to Fig. 2A ). The bioprosthetic mitral leaflets appear normal. View Video 6 at http://movie-usa.glencoesoftware.com/ video/10.1530/ERP-17-0004/video-6.
Video 7
Three-dimensional en face view (left atrial perspective). The mitral valve area is improved (compared to Fig. 1D 
Video 5
Intraoperative mid-esophageal 2-chamber TEE image demonstrates thin and pliable bioprosthetic mitral leaflets after 5 days of intravenous heparin (compare to Fig. 1A and B) . The left atrial thrombus remains. View Video 5 at http://movie-usa.glencoesoftware.com/ video/10.1530/ERP-17-0004/video-5.
